Lymphomas

B-cell lymphoma

  • Payer evidence dossiers in B-Cell lymphoma
  • Development of a budget impact model for primary mediastinal B-cell lymphoma (PMBCL)
  • Literature review and preparation of a PRO strategy in large B-cell lymphoma
  • Burden of diffuse large B-cell lymphoma on patients and caregivers
  • e-v@luate platform in diffuse large B-cell lymphoma

Hodgkin’s lymphoma

  • Payer evidence dossiers in non-Hodgkin’s lymphoma
  • Early payer engagement deck in classical Hodgkin’s lymphoma
  • Analyses of endpoints in oncology: Statistical analyses in Hodgkin’s lymphoma
  • Clinical trial analyses to support health-related quality of life in Hodgkin’s lymphoma

Non-Hodgkin’s lymphoma

  • Update of a payer evidence dossier in non-Hodgkin’s lymphoma
  • Literature review and conceptual mapping in non-Hodgkin’s lymphoma
  • Strategic PRO endpoint support, gap analysis and patient interviews in a biological therapy treatment for non-Hodgkin’s lymphoma
  • Validation of a patient satisfaction questionnaire in non-Hodgkin’s lymphoma
  • Conference poster and slide deck on non-Hodgkin’s lymphoma
  • Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, follicular non-Hodgkin’s lymphoma

Lymphomas (other)

  • Core value dossier and value proposition in cutaneous T-cell lymphoma
  • Development of a budget impact tool for a treatment for chronic lymphatic lymphoma for Spain
  • Support programme for reimbursement submissions in cutaneous T-cell lymphoma
  • Strategic consulting for a lymphoma trial
  • Clinical trial analysis of health-related quality of life data in patients with previously untreated follicular lymphoma
  • Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, and follicular non-Hodgkin’s lymphoma

Related categories

Experience,  Oncology,  Therapeutic area